Clinical Trials Sponsored by Ipsen Biopharmaceuticals

Total 1111 results

Keryx Biopharmaceuticals

Completed

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

Kidney Failure | Hyperphosphatemia

United States, Israel, Puerto Rico
Navidea Biopharmaceuticals

Completed

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Melanoma | Breast Cancer

United States
Nabi Biopharmaceuticals

Completed

A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

Smoking Cessation | Nicotine Dependence

United States
Nabi Biopharmaceuticals

Completed

A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers

Smoking

United States
Nabi Biopharmaceuticals

Completed

A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation

Smoking Cessation

United States
Kythera Biopharmaceuticals

Completed

Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat Tissue

Healthy

United States
XTL Biopharmaceuticals

Terminated

A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Chronic Peripheral Neuropathy Pain in Diabetics

United States
OMRIX Biopharmaceuticals

Unknown

Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil

Bilateral Ovarian Disease

United States, Spain, United Kingdom, Germany
Nabi Biopharmaceuticals

Completed

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Arteriosclerosis | Hyperparathyroidism, Secondary | Calcinosis

United States
Nabi Biopharmaceuticals

Terminated

Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease (SHIELD-2)

Staphylococcal Infections | Chronic Kidney Failure

United States
Angitia Biopharmaceuticals

Recruiting

A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion

Degenerative Disc Disease

China
Navidea Biopharmaceuticals

Recruiting

Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Rheumatoid Arthritis

United States
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Angitia Biopharmaceuticals

Completed

A Phase I/II Study of AGA111 for Lumbar Interbody Fusion in Patients With Degenerative Disc Disease

Degenerative Disc Disease

China
Navidea Biopharmaceuticals

Completed

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

Arthritis, Rheumatoid

United States
Keryx Biopharmaceuticals

Completed

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial) (COMPASS)

Chronic Kidney Diseases | Iron Deficiency Anemia

United States
Kythera Biopharmaceuticals

Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Healthy | Submental Fat

United States, Canada, Australia, United Kingdom
Kythera Biopharmaceuticals

Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Navidea Biopharmaceuticals

Withdrawn

Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid
Kythera Biopharmaceuticals

Completed

Condition of Submental Fullness and Treatment Outcomes Registry (CONTOUR)

Submental Fullness

United States, Canada
Keryx Biopharmaceuticals

Completed

KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD

Anemia of Chronic Kidney Disease

United States
Keryx Biopharmaceuticals

Completed

Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Iron Deficiency Anemia | Iron Deficiency

United States
Navidea Biopharmaceuticals

Withdrawn

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Navidea Biopharmaceuticals

Unknown

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Dementia | Alzheimer's Disease

United States
Eiger BioPharmaceuticals

Terminated

Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)

Hepatitis D

United States
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

Lipoma

United States
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Kythera Biopharmaceuticals

Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Moderate or Severe Submental Fullness

United States
Navidea Biopharmaceuticals

Terminated

Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Kythera Biopharmaceuticals

Completed

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Healthy

United States
Kythera Biopharmaceuticals

Completed

Evaluation of the Effect of ATX-101 on QT/QTc Intervals (ATX-101-11-24)

Healthy

United States
Nabi Biopharmaceuticals

Completed

Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever

Staphylococcal Infections
Kythera Biopharmaceuticals

Completed

A Study to Assess Injection Comfort of Two Formulations of ATX-101

Healthy

United States
OMRIX Biopharmaceuticals

Completed

Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy (Fleece)

Nephrectomy | Hemostatic Techniques

Israel
Nabi Biopharmaceuticals

Completed

StaphVAX in Cardiovascular Surgery Patients

Cardiovascular Diseases | Staphylococcal Infections | Cardiovascular Surgical Procedures

United States
XTL Biopharmaceuticals

Unknown

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

Hepatitis C

United States, Israel
Nabi Biopharmaceuticals

Completed

Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis

Kidney Failure, Chronic | Staphylococcal Infections
Keryx Biopharmaceuticals

Not yet recruiting

Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Eiger BioPharmaceuticals

Active, not recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)

Hepatitis Delta Virus

United States, France, Belgium, Spain, Italy, Turkey, Bulgaria, Germany, Israel, Romania, Georgia, Moldova, Republic of
Navidea Biopharmaceuticals

Completed

Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging

Rheumatoid Arthritis

United States
Eiger BioPharmaceuticals

Terminated

Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1) (LIBERTY2)

Pulmonary Arterial Hypertension

United States, Canada
Eiger BioPharmaceuticals

Completed

Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive (CLEAN-1)

Hepatitis C
Eiger BioPharmaceuticals

Withdrawn

A Study of Lonafarnib With or Without Ritonavir in Patients With HDV (LOWR-5)

Chronic Delta Hepatitis
Kythera Biopharmaceuticals

Completed

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Efficacy | Safety | Moderate to Severe Convexity of Submental Fat

United States
Navidea Biopharmaceuticals

Completed

An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

Nonalcoholic Steatohepatitis | NASH - Nonalcoholic Steatohepatitis

United States
Navidea Biopharmaceuticals

Unknown

Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI) (NAV4-04)

Mild Cognitive Impairment

United States
Navidea Biopharmaceuticals

Unknown

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

Alzheimer Disease

United States
Kythera Biopharmaceuticals

Completed

Phase 2 Study for the Treatment of Superficial Lipomas

Lipoma

United States
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Kythera Biopharmaceuticals

Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

United States, Canada

3

Subscribe